Dopavision
Ida Zündorf, PhD has a wealth of work experience. Ida has been the Clinical Research Director at Dopavision since 2020, the Associate Director Clinical Affairs at Cardiobridge GmbH since 2018, the Director of Clinical Studies at Retina Implant AG since 2017, the Clinical Studies & Market Access at Okuvision GmbH (Tochterunternehmen der Retina Implant AG) since 2015, the Qualifizierung in Wirtschaft und Management at SWA Steuer- & Wirtschaftsakademie GmbH since 2014, and the Scientific Researcher at Hertie Institute for Clinical Brain Reseach since 2007.
Ida Zündorf completed their Bachelor's degree in Psychology from Universidad de La Sabana between 1999 and 2004. Ida then went on to pursue a Master of Science (M.Sc.) in Neural and Behavioural Sciences from the Graduate School of Neural and Behavioural Sciences - International Max Planck Research School between 2005 and 2007. Finally, they earned their Doctor of Philosophy (PhD) in Neural and Behavioural Sciences from the Graduate School of Neural and Behavioural Neuroscience - International Max Planck Research School between 2007 and 2014.
This person is not in any offices
Dopavision
1 followers
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopia progression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.